IAD vs. CAD in men with hormone-sensitive, metastatic prostate cancer

Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer.

Key presentations at ASCO today on advanced prostate cancer

The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.

Abiraterone acetate in chemotherapy-naive mCRPC — Phase III trial outcome

This morning, at the ASCO annual meeting, Dr. Charles Ryan will present the full interim results of COU-AA-302, the randomized, Phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC).

Do African Americans do worse than Caucasians on active surveillance?

Data to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) on Sunday, June 3, suggest that African American men with localized prostate cancer may be less likely that Caucasian men to respond well to active surveillance as a management strategy. However, this conclusion comes from a retrospective analysis of [...]

Two important new trials of enzalutamide and cabozantinib for patients with mCRPC

According to media releases from the relevant companies, two significant trials (of enzalutamide and of cabozantinib) are already or will soon be recruiting men with metastatic, castration-resistant prostate cancer (mCRPC).

AUA drops use of the term “screening” in association with appropriate use of PSA testing

Yesterday evening, the American Urological Association (AUA) issued a new, formal statement on the role of PSA testing in assessment of risk for prostate cancer: “Information Sheet: Prostate-specific antigen (PSA) testing for the early detection of prostate cancer.”

Effects of ketoconazole, abiraterone, and chemotherapy in men with CRPC

Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy.

Managing advanced prostate cancer: what’s going to be presented at ASCO

So there are going to be > 180 papers specific to the management of prostate cancer presented at the annual meeting of the American Society of Clinical Oncology (ASCO) starting in Chicago next weekend. Some will be trivial; several will be “interesting”; a very few will be important.

Active surveillance in the “real world” of clinical practice today

A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the “real world” of clinical practice (as opposed to clinical trials and case series at academic medical centers).

The management of anorgasmia after radical prostatectomy: a role for cabergoline?

A paper presented earlier this week at the annual meeting of the American Urological Association in Atlanta suggests that a drug called cabergoline may have the ability to induce the return of orgasm in men with anorgasmia (the persistent or frequent absence of orgasm after normal sexual arousal). The available data suggests that the patients [...]

Discussion of USPSTF recommendation continues apace

Many readers of this blog will enjoy reviewing the editorial commentary in today’s issue of the influential USA Today, entitled “Skipping prostate test can kill“.

Baseline PSA levels and 10-year risk for a diagnosis of prostate cancer

Earlier, retrospective studies based on Swedish and Danish databases have suggested that men in their 40s with a single PSA level of < 1.0 ng/ml are at low risk for a diagnosis of prostate cancer for up to 30 years after that initial, baseline PSA result.

Prostate cancer “spread through the air” … NOT!

How did we all miss this? This may be the single most important paper presented at the annual meeting of the American Urological Association this year!

At least one intelligent response to the USPSTF recommendation

Dan Zenka, a prostate cancer patient and a Senior VP with the Prostate Cancer Foundation, appears to have published one of the more intelligent responses to the USPSTF recommendation on PSA screening since Monday’s announcement. Have a look at his blog post.

GUMDROP — or how some specialists collaborate to help their patients

An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients.

Follow

Get every new post delivered to your Inbox.

Join 333 other followers